Bharat Doshi - Dr Reddys Non-Executive Independent Director

RDY -- USA Stock  

USD 39.11  1.10  2.89%

Mr. Bharat Narotam Doshi serves as a NonExecutive Independent Director of the company. He joined our Board in May 2016. He is a former Executive Director and Group CFO of Mahindra Mahindra Limited. He was also the Chairman of Mahindra Mahindra Financial Services Limited since April 2008 and he stepped down from this position on his nomination as Director on the Central Board of Directors of the Reserve Bank of India in March 2016. He is the Chairman of Mahindra Intertrade Limited and a Director on the Board of Mahindra Holdings Limited. He is also an Independent Director of Godrej Consumer Products Limited. He also serves on the Advisory Board of Excellence Enablers, an organisation committed to promoting corporate governance in India
Age: 69  Director Since 2016  MBA    
91 40 4900 2900
Doshi is a Fellow Member of the Institute of Chartered Accountants of India and the Institute of Company Secretaries of India and holds a Master?s degree in Law from Bombay University. He is an alumnus of Harvard Business School and Fellow of the Salzburg Seminar on ?Asian Economies: Regional and Global Relationships?.

Management Efficiency

The company has Return on Asset of 5.42 % which means that on every $100 spent on asset it made $5.42 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 15.08 % implying that it generated $15.08 on every 100 dollars invested.
The company has 811.73M in debt with debt to equity (D/E) ratio of 23.5 . This implies that the company may be unable to create cash to meet all of its financial commitments. Dr Reddys Laboratories has Current Ratio of 1.85 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives


Terrence KearneyVertex Pharmaceuticals Incorpor
Yingqi XiaOrigin Agritech Limited
George SingRegeneron Pharmaceuticals
Ellen HoffingPerrigo Company plc
David BullockOrigin Agritech Limited
David GreenwayVertex Pharmaceuticals Incorpor
Christine PoonRegeneron Pharmaceuticals
Herman MorrisPerrigo Company plc
William DoyleZoetis
David AltshulerVertex Pharmaceuticals Incorpor
Jeffrey SmithPerrigo Company plc
Fei WangOrigin Agritech Limited
Huda ZoghbiRegeneron Pharmaceuticals
Michael JandernoaPerrigo Company plc
Lloyd CarneyVertex Pharmaceuticals Incorpor
Louise ParentZoetis
Donal OConnorPerrigo Company plc
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
Jacqualyn FousePerrigo Company plc
Min TangOrigin Agritech Limited
Robert ScullyZoetis

Entity Summary

Reddys Laboratories Limited operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 21966 people.Dr Reddys Laboratories Ltd (RDY) is traded on BATS Exchange in USA and employs 21,966 people.

Dr Reddys Laboratories Leadership Team

G Prasad, Co-Chairman of the Board, Chief Executive Officer, Managing Director
MARC KIKUCHI, Chief Executive Officer, North America Generics
Hans Hasler, Additional Independent Director
Leo Puri, Non-Executive Independent Director
Sandeep Poddar, Compliance Officer, Company Secretary
Satish Reddy, Co-Chairman of the Board
Kedar Upadhye, IR Contact Officer
Samiran Das, Executive Vice President Head - FTO and GGPM
Sauri Gudlavalleti, Global Head of Integrated Product Development Organization
YUGANDHAR PUVVALA, Global Head of Supply Chain
Amit Biswas, Executive Vice President - Integrated Product Development
Ravi Bhoothalingam, Non-Executive Independent Director
Alok Sonig, Senior Vice President & India Business Head (Generics)
Allan Oberman, Non-Executive Independent Director
J Ramachandran, Executive Vice President-Management Systems and Corporate Initiatives
Prasad Menon, Lead Non-Executive Independent Director
K Rao, Sr. Vice President & Head ? Chemical Technical Operations (CTO)
Abhijit Mukherjee, COO
Anil Namboodiripad, Global Head of Proprietary Products
Saumen Chakraborty, President, Chief Financial Officer and Global Head of ITBPE, Legal & Compliance and FMCRE
SANJAY SHARMA, Global Head of Manufacturing
Shikha Sharma, Non-Executive Independent Director
Sridar Iyengar, Non-Executive Independent Director
Ganadhish Kamat, Executive Vice President and Global Head-Quality
Sripada Chandrasekhar, President, Global Head of HR and Member of Management Council
Omkar Goswami, Non-Executive Independent Director
Erez Israeli, Chief Operating Officer and Global Head of Generics & PSAI
Kalpana Morparia, Non-Executive Independent Director
Bharat Doshi, Non-Executive Independent Director
J Moreau, Non-Executive Independent Director
Raymond Vre, Global Head of Biologics
Raghav Chari, Senior Vice President - Proprietary Products
Bruce Carter, Non-Executive Independent Director
Saunak Savla, IR Contact Officer
Ashok Ganguly, Non-Executive Independent Director
Umang Vohra, Executive Vice President Head - North America Generics
M Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets)
Cartikeya Reddy, Senior Vice President Head - Biologics
Anupam Puri, Non-Executive Independent Director
Archana Bhaskar, Chief Human Resource Officer
Deepak Sapra, Global Head of PSAI

Stock Performance Indicators

Current Sentiment - RDY

Dr Reddys Laboratories Investor Sentiment

Greater number of Macroaxis users are at this time bullish on Dr Reddys Laboratories Ltd. What is your opinion about investing in Dr Reddys Laboratories Ltd? Are you bullish or bearish?
98% Bullish
2% Bearish

Currently Active Assets on Macroaxis

Purchased few shares of
3 days ago
Traded for 188.14
Purchased a lot of shares of
3 days ago
Traded for 150.35
Purchased few shares of
3 days ago
Traded for 175.29
Purchased a lot of shares of
3 days ago
Traded for 152.77
Purchased over 300 shares of
3 days ago
Traded for 9.25
Additionally take a look at Your Equity Center. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.